Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 3 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
Morningstar· 17 hours agoFood and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. The submission ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 2 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 2 days agoIn addition, immune system irregularities, higher diagnosis rates, increased focus on early...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 2 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 1 day agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis& ...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 2 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 ...
AbbVie (NYSE:ABBV) Shares Up 0%
ETF DAILY NEWS· 6 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0% during mid-day trading on Thursday . The company traded as high as $166.45 and last traded at $166.15. ABBV has been the topic ...
Gerber LLC Makes New $342,000 Investment in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 4 days agoGerber LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission ...